coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Chester East PCN, Cheshire West and Chester (LAD) · Health Inequalities Profile

    PCN U07776 · NHS Cheshire and Merseyside Integrated Care Board · 4 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    38,654

    Registered population

    59.3% aged 18–64

    21.7%

    Aged 65+

    ICB 19.0% · England 17.9%

    7.8%

    Ethnic minority (non-White)

    3.8% Asian · England 9.6%

    2.7%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~998

    Core20 residents (est.)

    Resident basis; registered basis ~1,110 · see page 3

    5,959

    Hypertension register

    +8.51% in 3 yrs · England +5.60%

    355

    SMI register

    9.4% of Cheshire West and Chester (LAD)'s

    505

    COPD register

    Reviews +4.45% in 3 yrs

    Forecast to 2030

    7,209

    Hypertension patients, 2030

    +1,250 on today

    79.1%

    QRISK ≥20% on statins, 2030

    +7.08pp over 3 yrs

    5.7%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    56.3%
    Asthma annual review coverage trails benchmarks.

    Only 56.3% of the 2,583 asthma patients had a review, trailing England (65.7%) and leaving about 1,100 patients unreviewed.

    1.3%
    Recorded COPD prevalence sits below comparators.

    Crude COPD prevalence is 1.3% versus 2.1% locally and 1.9% nationally (-2.5% three-year change; +227 to +324 benchmark gap), which may reflect unverified under-detection.

    +12.9%
    Lipid therapy uptake grew faster than England.

    Lipid-lowering therapy for patients with QRISK ≥ 20% rose +12.9% over 2023 to 2025 (England +6.2%), reaching 62.1% coverage.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Patients aged 65+ comprise 21.7% of registered list, above England's 17.9%

    Chester East PCN serves 38,654 registered patients across its member practices, with an older age profile: 21.7% (8,404 patients) are aged 65+, above Cheshire West and Chester (LAD) (20.3%), NHS Cheshire and Merseyside Integrated Care Board (19.0%) and England (17.9%). Working-age adults (18–64) comprise 59.3% and children (0–17) 19.0%. Census estimates for associated resident areas indicate 92.2% are White, below the LAD (95.3%) and ICB (93.0%) but above England (81.1%), with an ethnic minority share of 7.8%. Registered patient counts and Census resident estimates use different population bases.

    Age profile

    0–1719.0%
    18–6459.3%
    65+21.7%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White92.2%
    Asian3.8%
    Mixed2.0%
    Other1.1%
    Black0.9%

    Older people · falls rows are Cheshire West and Chester (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Cheshire West and Chester LA)2,1092,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)84.7%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)59.1%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Cheshire West and Chester LA)8931,0219552024/25
    Falls deaths, all ages, per 100,000 (Cheshire West and Chester LA)14.918.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation is 2.7% overall and reaches 7.4% at Park Medical Centre

    The PCN records an average IMD decile of 7.8 and a Core20 share of 2.7%, below Cheshire West and Chester (15.7%), the ICB (31.9%), and England (21.0%). Across practices, Core20 share spans a 7.4 pp range, from 7.4% at Park Medical Centre (736 estimated patients) to 0.0% at Heath Lane Medical Centre. Practice estimates sum to 1,110 patients (2.9% weighted share) alongside 998 resident Core20 individuals; these distinct bases cannot be combined. Prioritise targeted outreach and service access at Park Medical Centre where deprivation is concentrated.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Park7.4% · 736 patients
    Upton Village2.0% · 164 patients
    Boughton Medical1.6% · 210 patients
    Heath Lane0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    355

    SMI register

    0.91% recorded prevalence

    151

    Learning disability register

    0.39% recorded prevalence

    26

    Care homes, 1,184 beds

    In the PCN catchment

    9.6%

    Provide unpaid care

    Cheshire West and Chester (LAD), Census 2021

    The PCN records 355 patients on its severe mental illness register (0.9%) and 151 with learning disabilities (0.4%, below England's 0.6%), alongside 26 catchment care homes with 1,184 beds. Borough figures (9.6% unpaid carers, 29 rough sleepers) are local authority estimates and cannot be extrapolated directly. Lower recorded learning disability prevalence may reflect coding differences or age structure, which register audits would test.

    Severe mental illness: physical health checks

    For SMI checks, 80.5% had blood pressure recorded (England 83.4%) and 78.8% had BMI checked (England 82.1%). Smoking cessation support fell 13.7 pp (England +0.1 pp) to 82.9% (England 94.2%), dropping to 51.2% at Park Medical Centre.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    5,959

    Hypertension register

    +8.51%

    Register growth, 3 yrs

    Cheshire West and Chester (LAD) +6.60% · England +5.60%

    +2.04pp

    BP control, under 80

    ≤140/90 · −0.25pp aged 80+

    +1,250

    More patients by 2030

    Forecast 7,209 (17.98%)

    Hypertension case-finding and control

    Chester East PCN records 5,959 hypertension patients (15.3% prevalence), in line with England (15.2%) but below Cheshire West and Chester (LAD) (17.0%) and the ICB (16.8%). Although 88.7% of patients had a recent blood pressure reading (England 90.0%), treatment to target reaches 66.8%, below England (70.3%), the borough (68.9%), and the ICB (69.1%). For patients aged under 80, control sits at 63.4% (England 67.8%, ICB 66.4%), falling to 59.3% at Heath Lane Medical Centre. Blood pressure control below England despite strong testing reach suggests prioritising medication titration and reviews could help close control gaps.

    Lipids and statins

    For patients with QRISK ≥ 20%, 62.1% receive lipid-lowering therapy, trailing England (63.6%) and Cheshire West and Chester (LAD) (63.8%) despite a +12.9% three-year increase (England +6.2%). Fewer high-risk patients receive lipid-lowering therapy than national rates suggest, so a recall audit could help address primary prevention gaps.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202652,558£1.60£1.71£1.86£84,093
    Cardiovascular (all), 202575,621£6.26£4.37£3.33£473,387

    In 2026, lipid-regulating drugs cost £1.60 per item across 52,558 items, below England (£1.86) and the ICB (£1.71) but above Cheshire West and Chester (LAD) (£1.44), spending £13,665 less than at England's unit cost. Unit costs below England may provide scope to expand therapy to untreated high-risk patients.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +7.95%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −0.54%

    Asthma prevalence, PCN 3-yr % change

    COPD prevalence is 1.3% (505 patients), falling 2.5% over 2023 to 2025 (England +2.6%), below Cheshire West and Chester (LAD) (2.1%) and England (1.9%), with a benchmark gap of +227 to +324 patients. COPD reviews reach 72.3% (England 76.4%). Asthma prevalence is 7.0% (2,583 patients), but reviews cover 56.3% (England 65.7%), leaving about 1,100 patients without a recorded review. For asthma patients aged 6–19, second-hand smoke status recording is 63.4% (England 78.8%).

    Cancer register and children's immunisation

    The cancer register records 1,741 patients (4.5% prevalence vs England 3.8%), rising +13.2% over 2023 to 2025 (England +9.0%). In childhood immunisations in Q1 2025/26, 12-month 6-in-1 coverage is 90.1% (below the 95.0% target by 4.9 pp; England 91.0%) and 24-month MMR dose 1 is 92.9%. By age 5, MMR dose 1 reaches 98.8% and dose 2 reaches 97.6% (a 1.2 pp dose difference).

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months90.1%

    England 91.0%

    6-in-1 complete primary course at 24 months94.3%

    England 92.2%

    MMR dose 1 at 24 months92.9%

    England 88.3%

    MMR dose 2 at age 597.6%

    England 82.8%

    4-in-1 pre-school booster at age 595.1%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    In NHS Cheshire and Merseyside ICB, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2 in 2022, below the 75.0% national ambition and requiring about 2,640 extra early diagnoses annually, with staged cancers representing 72.8% of registered cancers (these data describe the wider ICB system, not PCN performance). Chester East PCN records 1,741 cancer patients (4.5% prevalence), rising +13.2% over 2023 to 2025 (England +9.0%). PCN cervical screening coverage is 73.5% (England 66.8%), but Park Medical Centre records 69.3% after a -6.7% three-year change. Prioritising cervical screening recall where uptake lags could help protect early cancer detection.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026, Countess of Chester Hospital NHS Foundation Trust met the cancer 28-day faster diagnosis standard at 87.4%, outperforming North Cheshire and Mersey NHS Foundation Trust (80.2%), Liverpool University Hospitals NHS Foundation Trust (75.5%), the ICB (77.2%) and England (79.3%). However, its 62-day standard reached 83.3% against the 85.0% target (ICB 76.2%, England 71.2%), and its 31-day treatment standard was 93.5% against the 96.0% standard. Diagnostic six-week waits reached 26.4% for colonoscopy and 11.3% for MRI. These provider-level measures reflect system capacity rather than PCN performance.

    Pathways within standard (%)Countess of ChesterNorth Cheshire and MerseyLiverpoolCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)87.3780.2175.4777.2579.32
    31-day treatment (96%)93.4898.1790.5195.7192.50
    62-day referral to treatment (85%)83.2883.6773.2676.2371.16
    Diagnostic waits over 6 weeks (%)Countess of ChesterNorth Cheshire and MerseyLiverpoolEngland
    MRI11.260.536.4221.40
    CT4.182.320.719.92
    Echocardiography31.4428.0412.5528.48
    Colonoscopy26.4415.9833.1430.83
    Gastroscopy27.5220.2444.9929.02
    All 15 DM01 tests20.166.3411.5023.14
    Community services activityCheshire West and Chester residentsCheshire and Merseyside ICB
    Care contacts47,655541,280
    Referrals10,32597,150
    Patients with a contact18,585146,240

    Community services (residents of Cheshire West and Chester), Jun 2026 (provisional). In Cheshire West and Chester, community services recorded 47,655 total contacts in June 2026 (provisional), with adults aged 65+ accounting for 25,095 contacts or 52.7% of the total activity. This upper-tier authority volume highlights substantial local community demand among older residents, although the figures represent borough residents rather than PCN-specific activity.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Phone access spans 27.9 pp and vaccination achievement ranges 53.0 pp across practices

    In 2025/26, Park Medical Centre recorded 94.0% overall QOF achievement. Heath Lane Medical Centre recorded 99.8% overall QOF achievement. The England comparator was 92.5%. For QOF vaccination and immunisation-domain achievement, Park Medical Centre achieved 47.0%, while Heath Lane Medical Centre achieved 100.0%, showing a 53.0 pp practice range against the England figure of 55.2%.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Boughton Medical1151.668.2%79.7%91.5%
    Upton Village1102.070.5%73.2%86.5%
    Park1037.442.7%75.1%75.0%
    Heath Lane960.054.1%65.3%69.3%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNCheshire West and Chester (LAD)AssetPCNCheshire West and Chester (LAD)
    Care homes (catchment)26 (1,184 beds)n/aSchools (catchment)56n/a
    Children's centres115Places of worship36231
    Libraries216Food banks (VCS)n/a1
    Homelessness support (VCS)n/a1Day centres (VCS)n/a1
    Carers support groups (VCS)n/a1Primary schools (LA maintained)870
    Primary academies846Special schools25

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma annual review recall

    56.3% of 2,583 asthma patients had a review in the last 12 months, below the LAD (60.0%), ICB (62.3%) and England (65.7%), leaving 1,129 (about 1,100) unreviewed. For discussion: run structured recall using a single review template and trial flexible slots alongside inhaler prescribing checks. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    COPD case-finding and spirometry audit

    COPD prevalence is 1.3% (505 patients) after a -2.5% change (2023 to 2025), below England (1.9%, +2.6%) and the LAD (2.1%, +2.0%), a +227 to +324 patient gap. For discussion: search for smokers or ex-smokers with repeated respiratory prescribing lacking a COPD code, and raise spirometry capacity with system partners. Moderate effort to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Option 3

    Hypertension case-finding and titration review

    Hypertension prevalence is 15.3% (5,959 patients vs England 15.2%, ICB 16.8%, LAD 17.0%; -72 to +600 gap), while target control is 66.8% (England 70.3%) despite 88.7% BP recording. For discussion: search for repeated raised BP readings lacking a register code and run pharmacist-led titration reviews for uncontrolled patients. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Targeted Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Smoking cessation support review (p4)Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Hypertension blood pressure control review (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Infant immunisation recall protocol (p6)6-in-1 coverage at 12 months10YHP sickness to prevention · 95% targetPCN
    Targeted cervical screening recall (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026Practice
    Practice telephony and triage review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Structured asthma annual review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · COPD case-finding and spirometry audit (p12)COPD register · COPD: QOF prevalence · Aged 65+Core20PLUS5 approach · Tobacco and Vapes BillPCN
    Option 3 · Hypertension case-finding and titration review (p12)Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP readingCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15